未找到相关数据
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer
被引：2
作者：
Gerber, David E.
Ramalingam, Suresh S.
Morgensztern, Daniel
Kelly, Ronan Joseph
Burns, Timothy Francis
Lopez-Chavez, Ariel
Spigel, David R.
Wehbe, Ahmad Mouharnad
Sorensen, Rachel
Weaver, David T.
Horobin, Joanna
Keegan, Mitchell
Scaglioni, Pier P.
Camidge, D. Ross
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Washington Univ, St Louis VA Med Ctr, St Louis, MO USA
[4] Alvin Siteman Canc Ctr, St Louis, MO USA
[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[6] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA
[7] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[10] Verastem Inc, Cambridge, MA USA
[11] Univ Colorado, Ctr Canc, Aurora, CO USA
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps8126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8126
引用
收藏
页数：1
相关论文